The Technology Will Play an Important Role in
the Hospital's Plan to Expand Patient Access to High Precision
Radiation Therapy Treatments
MADISON,
Wis., Sept. 10, 2024 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that Gifu Prefectural
General Medical Center is setting a new standard in cancer care in
Japan as the first hospital in the
country to treat patients with surface-guided radiation therapy
(SGRT) using the company's Radixact® Radiation
Delivery System and VitalHold™* package. SGRT is designed to help
medical care teams to effectively position the patient and
confidently monitor the accuracy of that positioning throughout
treatment. The ability to confidently monitor also enables the deep
inspiration breath hold (DIBH) technique, which is often used in
left breast cancer treatment to help protect the heart from
radiation.
During treatment with SGRT, high resolution cameras continuously
monitor a patient's breathing and position in real-time to create a
3-dimensional map of a patient's skin. The image enables medical
care teams to easily visualize the difference between the current
body position and the target position, helping to ensure the
patient is appropriately positioned when radiation is
delivered.
"I am very pleased with the customer interest in Japan for VitalHold, our joint solution in
partnership with C-Rad, since we received Shonin approval at the
end of 2023. At Accuray, we are relentlessly focused on innovation
that improves the value of, and patient access to, our products.
The VitalHold technology reflects this focus, adding to the unique
benefits offered by the Radixact System and expanding options for
delivering high precision radiation treatments," said Sandeep Chalke, Senior Vice President, Chief
Commercial Officer and interim CEO at Accuray. "We are proud to
support Gifu Prefectural General Medical Center as they treat
the first patients in Japan with
the Radixact System and VitalHold. This is an important milestone
that I believe will accelerate their team's efforts to improve
access, outcomes and the patient experience."
Approximately 50 percent of all cancer patients need
radiotherapy at least once to cure their cancer, increase the
chance of cure or relieve symptoms caused by cancer1.
The Gifu Prefectural General Medical Center team is
focused on driving a fundamental change in the way cancer is
managed.
"We are delighted to announce the commencement of our hospital's
use of the Radixact System with VitalHold. In our efforts to
enhance the availability of radiation therapy delivered in our
department, which has long been a challenge, we have constructed a
new building, introduced the Radixact System and will initiate
treatments with the Accuray CyberKnife® S7™ System at a
later date. One of the reasons we decided to switch from an older
C-arm linear accelerator, which we have been using for many years,
to the Radixact System, is to take advantage of the unique benefits
of helical imaging and delivery in combination with the
capabilities of VitalHold," said Yuichi
Kajiura, M.D., department of radiation oncology, Gifu
Prefectural General Medical Center.
Continued Dr. Kajiura, "By using VitalHold, we can set up
patients faster than initially anticipated and monitor the
patient's position throughout the radiation treatment. With the use
of hypofractionation, or the delivery of increased dose per
session, monitoring the patient's position during irradiation has
become extremely important. These factors enable us to deliver
highly accurate treatments and will help us to provide the highest
quality medical services to our patients."
At Gifu Prefectural General Medical Center, the team is using
ClearRT™ to produce diagnostic-like quality images that will
empower them to make more informed decisions about all aspects of
their patients' treatments. To date, ClearRT has facilitated
accurate patient alignment - with clearer images - than
conventional MVCT. ClearRT has also enabled the Gifu team to plan
and deliver more precise treatments, by providing them with the
ability to clearly see changes in the contours of the body and the
shape of the tumor due to daily radiation therapy.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn, X,
and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited to, expectations regarding the
company's products and upgrades; expectations regarding patient
access and cancer management in Japan; clinical applications; clinical
results; patient experiences and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product
innovations and releases; the company's ability to develop new
products or improve existing products to meet customers' needs; the
company's ability to anticipate or keep pace with changes in the
marketplace; and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's quarterly report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
May 8, 2024, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
*VitalHold availability is subject to regulatory clearance or
approval in some markets.
1 INTERNATIONAL ATOMIC ENERGY AGENCY, Radiotherapy in
Cancer Care: Facing the Global Challenge, Non-serial Publications ,
IAEA, Vienna (2017)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gifu-prefectural-general-medical-center-achieves-milestone-with-treatment-of-the-first-cancer-patients-in-japan-using-the-accuray-radixact-system-and-vitalhold-solution-302243466.html
SOURCE Accuray Incorporated
